RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation

Journal of Cellular Biochemistry

Volumn 112, Issue 3, 2011, Pages 933-941

  Chen, Li Mien ^a,b   Kuo, Chia Hua ^c   Lai, Tung Yuan ^d,e   Lin, Yueh Min ^f   Su, Cheng Chuan ^g,h   Hsu, His Hsien ⁱ   Tsai, Fuu Jen ^e   Tsai, Chang Hai ^j   Huang, Chih Yang ^d,e,j   Tang, Chih Hsin ^a,d  

^a CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF TAIPEI   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^h TZU CHI UNIVERSITY   (Taiwan)

ⁱ MACKAY MEMORIAL HOSPITAL   (Taiwan)

^j ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

ERK; Lung cancer; Migration; RANK; RANKL

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; I KAPPA B; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

ARTICLE; CANCER CELL; CELL ASSAY; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, REPORTER; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LUCIFERASES; LUNG NEOPLASMS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; NF-KAPPA B; PHOSPHORYLATION; RANK LIGAND; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79951804629     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23009     Document Type: Article

References (33)

1. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. 2008. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68:92-104.
2. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342. (Pubitemid 40852708)
3. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. 2006. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107:289-298. (Pubitemid 44036558)
4. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, Chuang SE, Chen MW, Hua KT, Wu YL, Cha ST, Babu MS, Chen CN, Lee PH, Chang KJ, Kuo ML. 2007. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120:2053-2065. (Pubitemid 47010001)
5. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. 1998. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 273:20551-20555. (Pubitemid 28377625)
6. Darnay BG, Ni J, Moore PA, Aggarwal BB. 1999. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274:7724-7731.
7. Desgrosellier JS, Cheresh DA. 2010. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
8. Duperray A, Languino LR, Plescia J, McDowall A, Hogg N, Craig AG, Berendt AR, Altieri DC. 1997. Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem 272:435-441. (Pubitemid 27021177)
9. Fong YC, Li TM, Wu CM, Hsu SF, Kao ST, Chen RJ, Lin CC, Liu SC, Wu CL, Tang CH. 2008. BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway. J Cell Physiol 217:846-855.
10. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001. Cancer statistics, 2001. CA Cancer J Clin 51:15-36. (Pubitemid 32166444)
11. Gridelli C, Rossi A, Maione P. 2003. Treatment of non-small-cell lung cancer: State of the art and development of new biologic agents. Oncogene 22:6629-6638. (Pubitemid 37372343)
12. Gupta GP, Massague J. 2006. Cancer metastasis: Building a framework. Cell 127:679-695. (Pubitemid 44781029)
13. Heymann MF, Riet A, Le Goff B, Battaglia S, Paineau J, Heymann D. 2008. OPG, RANK and RANK ligand expression in thyroid lesions. Regul Pept 148:46-53.
14. Huang WC, Chen CC. 2005. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25:6592-6602.
15. Huang WC, Chan ST, Yang TL, Tzeng CC, Chen CC. 2004. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: Molecular and functional study of novel alpha-methylene-gamma- butyrolactone derivatives. Carcinogenesis 25:1925-1934.
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. 2005. Cancer statistics, 2005. CA Cancer J Clin 55:10-30. (Pubitemid 40310185)
17. Kapur S, Baylink DJ, Lau KH. 2003. Fluid flow shear stress stimulates human osteoblast proliferation and differentiation through multiple interacting and competing signal transduction pathways. Bone 32:241-251. (Pubitemid 36349527)
18. Kearns AE, Khosla S, Kostenuik PJ. 2008. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155-192. (Pubitemid 351519689)
19. Knauf JA, Fagin JA. 2009. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 21:296-303.
20. Lawson C, Wolf S. 2009. ICAM-1 signaling in endothelial cells. Pharmacol Rep 61:22-32.
21. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. 1997. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713. (Pubitemid 28156637)
22. Madrid LV, Mayo MW, Reuther JY, Baldwin AS, Jr. 2001. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276:18934-18940.
23. Makrilia N, Kollias A, Manolopoulos L, Syrigos K. 2009. Cell adhesion molecules: Role and clinical significance in cancer. Cancer Invest 27: 1023-1037.
24. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF. 2005. Role of ICAM1 in invasion of human breast cancer cells. Carcino-genesis 26:943-950. (Pubitemid 41214323)
25. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. 1999. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274:30353-30356.
26. Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH. 2008. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 29:1483-1492.
27. Tang CH, Yamamoto A, Lin YT, Fong YC, Tan TW. 2010. Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochem Pharmacol 79:209-217.
28. Van Campenhout A, Golledge J. 2009. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204:321-329.
29. van de Stolpe A, van der Saag PT. 1996. Intercellular adhesion molecule-1. J Mol Med 74:13-33.
30. Viatour P, Merville MP, Bours V, Chariot A. 2005. Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 30:43-52. (Pubitemid 40093740)
31. Virk MS, Petrigliano FA, Liu NQ, Chatziioannou AF, Stout D, Kang CO, Dougall WC, Lieberman JR. 2009. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 44:160-167.
32. Yeh YY, Chiao CC, Kuo WY, Hsiao YC, Chen YJ, Wei YY, Lai TH, Fong YC, Tang CH. 2008. TGF-beta1 increases motility and alphavbeta3 integrin upregulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochem Pharmacol 75:1292-1301.
33. Zimmerman T, Blanco FJ. 2008. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: Design and mechanism of action. Curr Pharm Des 14:2128-2139.